Showing results (1-10 of 224) with videos related to
Sort By:
Pageof 23
Journal of Alzheimer'S Disease : JAD|June 28, 2012
Amyloid-β peptide: Dr. Jekyll or Mr. Hyde?Daniela Puzzo, Ottavio ArancioCurrent Alzheimer Research|July 18, 2006
Fibrillar beta-amyloid impairs the late phase of long term potentiationDaniela Puzzo, Ottavio ArancioReviews in the Neurosciences|December 22, 2006
Involvement of the nitric oxide pathway in synaptic dysfunction following amyloid elevation in Alzheimer's diseaseDaniela Puzzo, Agostino Palmeri, Ottavio ArancioNeuropsychiatric Disease and Treatment|August 30, 2008
Role of phosphodiesterase 5 in synaptic plasticity and memoryDaniela Puzzo, Salvatore Sapienza, Ottavio Arancio, et al.Expert Opinion on Drug Discovery|May 1, 2015
Rodent models for Alzheimer's disease drug discoveryDaniela Puzzo, Walter Gulisano, Agostino Palmeri, et al.Biochemical Pharmacology|January 28, 2014
Behavioral assays with mouse models of Alzheimer's disease: practical considerations and guidelinesDaniela Puzzo, Linda Lee, Agostino Palmeri, et al.Neuropharmacology|June 10, 2018
Sub-efficacious doses of phosphodiesterase 4 and 5 inhibitors improve memory in a mouse model of Alzheimer's diseaseWalter Gulisano, Maria Rosaria Tropea, Ottavio Arancio, et al.The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|July 22, 2005
Amyloid-beta peptide inhibits activation of the nitric oxide/cGMP/cAMP-responsive element-binding protein pathway during hippocampal synaptic plasticityDaniela Puzzo, Ottavio Vitolo, Fabrizio Trinchese, et al.Journal of Molecular Neuroscience : MN|August 18, 2004
Cell cultures from animal models of Alzheimer's disease as a tool for faster screening and testing of drug efficacyFabrizio Trinchese, Shumin Liu, Ipe Ninan, et al.Free Radical Biology & Medicine|November 18, 2022
Nitric oxide/cGMP/CREB pathway and amyloid-beta crosstalk: From physiology to Alzheimer's diseaseMaria Rosaria Tropea, Walter Gulisano, Valeria Vacanti, et al.Pageof 23